Fig. 1

Immuno-oncology screening platform identifies statins as enhancers of immune cell-induced cancer cell death. (a) Schematic of the miniaturized 384-well plate-based model system used for drug screening: HCT116-GFP cells cultured as monoculture or co-cultured with anti-CD3/IL2 activated PBMCs at a 1:1 ratio. (b) Z-immunomodulation (Z_m) and Z-immunopotentiation (Z_p) calculated over time, based on GFP-signal in untreated HCT116-GFP cells in monoculture, PBMCs in monoculture, or co-cultured cells quantified every 4 h for 96 h. Results are shown as mean ± SD from four independent experiments (n = 64). (c) Viability of HCT116-GFP cells, indirectly measured by image-based quantification of GFP intensity, in monoculture (y-axis) and in co-culture (x-axis) 72 h after addition of the Prestwick Chemical Library drugs at a final drug concentration of 10 µM. Hit compounds selected for validation experiments are encircled in red. (d) Viability of HCT116-GFP cells, cultured as monoculture or co-cultured with PBMCs at a 1:4 ratio, 72 h after treatment with newly purchased hit compounds at a final concentration of 10 µM for validation (n = 3)